Hoping for EU approval of Synthes acquisition, J&J will sell trauma unit to Biomet
Johnson & Johnson announced on Tuesday that it will divest the trauma segment of DePuy Orthopaedics (its medical device division) in hopes of winning EU approval for its acquisition of Synthes. The asset will be sold to Biomet for $280 million.
Full content: Philadelphia Inquirer
Related content: Analyzing Medical Device Mergers
Featured News
South Dakota Reaches Settlement With NCAA Ahead of Antitrust Payout Approval
Apr 23, 2025 by
CPI
Judge Allows Yelp’s Antitrust Lawsuit Against Google to Proceed
Apr 23, 2025 by
CPI
Meta Lawyers Try to Undercut Instagram Co-Founder’s Damaging Testimony
Apr 23, 2025 by
CPI
Tyson Foods, Others Settle Pork Price-Fixing Suit for $64 Million
Apr 23, 2025 by
CPI
NJ Sues RealPage, Landlords Over Rent Collusion
Apr 23, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece